CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Li Tzong Chen, Andrea Wang-Gillam, Yan Shen Shan, Teresa Macarulla, Jean Frédéric Blanc, Richard Hubner, Chang Fang Chiu, Gilberto Schwartsmann, Jens Siveke, Pipas J. Marc, Bruce Belanger, Floris de Jong, Khalid Mamlouk, Daniel Von Hoff

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)iii6-iii7
JournalAnnals of Oncology
StatePublished - Jun 2017

Cite this